Lineage Cell Therapeutics (LCTX) Stock Overview
A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LCTX from our risk checks.
LCTX Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lineage Cell Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.26 |
| 52 Week High | US$2.09 |
| 52 Week Low | US$0.65 |
| Beta | 1.6 |
| 1 Month Change | -17.65% |
| 3 Month Change | -33.33% |
| 1 Year Change | 89.47% |
| 3 Year Change | -1.56% |
| 5 Year Change | -55.79% |
| Change since IPO | -63.12% |
Recent News & Updates
Recent updates
Cell Therapy Manufacturing And Partner Dependence Will Pressure Margins Yet Leave Long Runway
Catalysts About Lineage Cell Therapeutics Lineage Cell Therapeutics develops allogeneic cell therapies using its AlloSCOPE manufacturing platform for conditions linked to loss of specific cell function. What are the underlying business or industry changes driving this perspective?
LCTX: AlloSCOPE Platform Progress Will Support Future Pipeline Monetization Potential
Analysts have raised their price target on Lineage Cell Therapeutics by $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that reflect recent bullish coverage and target revisions from the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to recent target revisions as support for a higher fair value, suggesting that prior assumptions for revenue growth, profit margins, and future P/E were conservative.Aging Trends And Regenerative Medicine Will Open New Avenues
Lineage Cell Therapeutics' higher net profit margin and a slight increase in its discount rate have contributed to a raised consensus analyst price target, now at $4.17. What's in the News First-ever chronic spinal cord injury patient treated in Lineage's DOSED clinical study, which evaluates a novel device for delivering OPC1 cells directly to injury sites; OPC1 has received RMAT and Orphan Drug designations from the FDA.Advancements In OpRegen And Genentech Collaborations Will Unlock Potential
Strong data support and partnership expansions, especially for OpRegen, could significantly enhance future revenue and market share in dry AMD.Shareholder Returns
| LCTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.1% | 1.2% | 1.6% |
| 1Y | 89.5% | 35.1% | 28.2% |
Return vs Industry: LCTX exceeded the US Biotechs industry which returned 35.1% over the past year.
Return vs Market: LCTX exceeded the US Market which returned 28.2% over the past year.
Price Volatility
| LCTX volatility | |
|---|---|
| LCTX Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LCTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LCTX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 75 | Brian Culley | www.lineagecell.com |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
Lineage Cell Therapeutics, Inc. Fundamentals Summary
| LCTX fundamental statistics | |
|---|---|
| Market cap | US$331.57m |
| Earnings (TTM) | -US$64.21m |
| Revenue (TTM) | US$14.78m |
Is LCTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LCTX income statement (TTM) | |
|---|---|
| Revenue | US$14.78m |
| Cost of Revenue | US$18.96m |
| Gross Profit | -US$4.18m |
| Other Expenses | US$60.03m |
| Earnings | -US$64.21m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -28.28% |
| Net Profit Margin | -434.44% |
| Debt/Equity Ratio | 0% |
How did LCTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 08:42 |
| End of Day Share Price | 2026/06/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lineage Cell Therapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |